Stocktake of PBS medicines available for endometriosis and related conditions, and comparison of current Australian pharmacological treatment guidelines (2022) Report
Page last updated: 28 March 2024
A ‘Stocktake of medicines listed on the Pharmaceutical Benefits Scheme (PBS) for the treatment of endometriosis and related conditions and comparison of current Australian pharmacological treatment guidelines’ report was considered by the Pharmaceutical Benefits Advisory Committee (PBAC) in December 2022. The purpose of the stocktake was to identify potential gaps between PBS-funded medicines and medicines available to patients privately (at full cost).
The Stocktake Report and a Consumer Summary are now available.
- Stocktake of PBS medicines available for endometriosis and related conditions, and comparison of current Australian pharmacological treatment guidelines (2022) (PDF 626 KB)
- Stocktake of PBS medicines available for endometriosis and related conditions, and comparison of current Australian pharmacological treatment guidelines (2022) (Word 74 KB)
- Consumer Summary-Stocktake of PBS medicines available for endometriosis and related conditions (PDF 284 KB)
- Consumer Summary-Stocktake of PBS medicines available for endometriosis and related conditions (Word 130 KB)
